Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 4,491 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer of Thorax Clear all

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: CP-751,871, paclitaxel, carboplatin, erlotinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 26
States / cities: Tucson, Arizona • Greenbrae, California • Los Angeles, California + 15 more

Conditions: Adult Solid Tumor
Interventions: CANscript; Diagnostic Test
Lead sponsor: Mitra RxDx, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Timeline: 2017 – 2019
U.S. locations: 30
States / cities: Gilbert, Arizona • Aurora, Colorado • Norwich, Connecticut + 23 more

Conditions: Carcinoma, Endometrial Adenocarcinoma, Neoplasms, Squamous Cell Carcinoma of the Anus, Adenocarcinoma of the Pancreas, Advanced Cancer, Solid Tumor, Solid Carcinoma, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Vulva, Squamous Cell Carcinoma of the Penis, Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma
Interventions: PEN-866 Sodium, fluorouracil, Folinic acid, Niraparib; Drug
Lead sponsor: Tarveda Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 16
States / cities: Springdale, Arkansas • Denver, Colorado • Fort Myers, Florida + 13 more

Conditions: Non Small Cell Lung Cancer
Interventions: IPI 504 plus Docetaxel, Placebo plus Docetaxel; Drug
Lead sponsor: Infinity Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 41
States / cities: Chandler, Arizona • Tucson, Arizona • Orange, California + 38 more

Conditions: Advanced Solid Tumors
Interventions: LCB84, Anti-PD-1 monoclonal antibody; Drug
Lead sponsor: LigaChem Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Los Angeles, California • Boston, Massachusetts • Ann Arbor, Michigan + 3 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: TLK286, carboplatin, paclitaxel; Drug
Lead sponsor: Telik; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 52
States / cities: Concord, California • Escondido, California • Hayward, California + 35 more

Conditions: Non-Small Cell Lung Cancer
Interventions: LGX818; Drug
Lead sponsor: Array Biopharma, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lung Cancer
Interventions: GL-ONC1; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Sarcoma, Melanoma, Epithelial Malignancies, Pleural Malignancies
Interventions: Cyclophosphamide, Allogenic tumor Cell Vaccine (K562), Celecoxib; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Primary Brain Tumors, Renal Cell Carcinoma, Sarcomas, Salivary Gland Cancers, Adult Solid Tumor
Interventions: Entrectinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 48
States / cities: Phoenix, Arizona • Duarte, California • La Jolla, California + 32 more

Conditions: Solid Tumor, Advanced Solid Tumor, Non Small Cell Lung Cancer, Colo-rectal Cancer
Interventions: MRTX0902, MRTX849; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 17
States / cities: New Haven, Connecticut • Newark, Delaware • Orlando, Florida + 13 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Rogers Sciences Inc.; Industry
Eligibility: Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Melanoma of Skin, Endometrial Cancer, Liver Cancer, Pancreatic Cancer, Rectal Cancer, Kidney Cancer, Other Solid Malignant Tumors
Interventions: Metformin, Coach Directed Behavioral Weight Loss, Self-control weight loss; Drug · Behavioral
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Lung Carcinoma, ALK Gene Rearrangement, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Brigatinib, Local Consolidation Therapy; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Thoracic Cancer, Spine Cancer, Thoracic Diseases, Spine Disease, Thoracic Neoplasms, Spine Metastases
Interventions: MRI with custom MRI spine coil; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Cancer
Interventions: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA); Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non Small Cell Lung Cancer, Lung Cancer
Interventions: ABT-751 and Carboplatin; Drug
Lead sponsor: Konstantin Dragnev; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Bone Metastases
Interventions: ExAblate 2000; Device
Lead sponsor: InSightec; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Pulmonary Nodule, Solitary, Pulmonary Cancer, Lung Cancer, Lung Cancer, Nonsmall Cell, Lung Adenocarcinoma
Interventions: Ion Endoluminal System; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Lung Cancer
Interventions: carboplatin, gefitinib, paclitaxel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Recurrent Colon Cancer, Extensive Stage Small Cell Lung Cancer, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Stage III Non-small Cell Lung Cancer, Stage I Pancreatic Cancer, Stage II Non-small Cell Lung Cancer, Stage IVB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Colon Cancer, Stage IVA Pancreatic Cancer
Interventions: Detox-B adjuvant, ras peptide cancer vaccine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Timeline: Started 1995
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Extensive Stage Small Cell Lung Cancer, Recurrent Colon Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Rectal Cancer, Recurrent Small Cell Lung Cancer, Stage IV Colon Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Rectal Cancer
Interventions: recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)-TRICOM vaccine, docetaxel, sargramostim; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Small Cell Lung Cancer, Non-small Cell Lung Cancer
Interventions: XMT-1001; Drug
Lead sponsor: Mersana Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 12
States / cities: Scottsdale, Arizona • Denver, Colorado • Indianapolis, Indiana + 9 more

Conditions: Breast Cancer, Chest Wall Disease
Interventions: Pembrolizumab, Carboplatin, Trastuzumab; Biological · Drug
Lead sponsor: Laura Huppert, MD, BA; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 7
States / cities: San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 4 more

Search by objective public record fields.

Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer

CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2

PEN-866 in Patients With Advanced Solid Malignancies

A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer

Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC

Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma

Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

A Novel Therapy for the Treatment of Chest Wall Progression of Breast Cancer

Survivorship Promotion In Reducing IGF-1 Trial

Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Studying a New Piece of Equipment That Can Help Plan Radiation Therapy of the Spine

EBUS TBNA After PET/CT in Diagnosing Patients With Stage I-IIA Non-small Cell Lung Cancer Evaluated for Stereotactic Body Radiation Therapy

Pharmacokinetic & Pharmacodynamic Study of ABT-751 With Carboplatin in Patients With Advanced Lung Cancer

MR Guided Focused Ultrasound Surgery of Metastatic Bone Tumors

Cios Mobile 3D Spin for Robotic Bronchoscopy

ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer

Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer

A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors

Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease